Biocryst Stock Analysis

BCRX
 Stock
  

USD 12.36  0.34  2.68%   

The current bullish price patterns experienced by current Biocryst Pharma shareholders could raise concerns from investors as the firm is trading at a share price of 12.36 on 2,263,900 in volume. The company executives have been very successful in rebalancing the firm assets at opportune times to take advantage of market volatility in August. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.0. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Biocryst Pharma partners.
Continue to Trending Equities.
  
The Biocryst Pharma stock analysis report makes it easy to digest most publicly released information about Biocryst Pharma and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Biocryst Stock analysis module also helps to analyze the Biocryst Pharma price relationship with some important fundamental indicators such as market cap and management efficiency.

Biocryst Stock Analysis Notes

About 73.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.09. Biocryst Pharma had not issued any dividends in recent years. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people. For more info on Biocryst Pharma please contact Jon Stonehouse at 919 859 1302 or go to https://www.biocryst.com.

Biocryst Pharma Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Biocryst Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Biocryst Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Biocryst Pharma has very high historical volatility over the last 90 days
Biocryst Pharma has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 188.03 M. Net Loss for the year was (193.97 M) with loss before overhead, payroll, taxes, and interest of (58.9 M).
Biocryst Pharma currently holds about 443.47 M in cash with (158.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.39.
Roughly 73.0% of the company shares are held by institutions such as insurance companies
Latest headline from investorplace.com: 3 Biotech Stocks to Buy Now for Extraordinary Gains - InvestorPlace

Biocryst Pharma Upcoming and Recent Events

Earnings reports are used by Biocryst Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Biocryst Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Biocryst Pharma SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Biocryst Pharma prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Biocryst Pharma investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Biocryst Pharma specific information freely available to individual and institutional investors to make a timely investment decision.
14th of September 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
25th of August 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
4th of August 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
7th of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
5th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View
11th of April 2022
Regulation FD Disclosure
View
8th of April 2022
Financial Statements and Exhibits. Other Events
View
23rd of February 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View

Biocryst Pharma Thematic Classifications

In addition to having Biocryst Pharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech
Biotechnology and pharmaceuticals production and services

Biocryst Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Biocryst Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biocryst Pharma backward and forwards among themselves. Biocryst Pharma's institutional investor refers to the entity that pools money to purchase Biocryst Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares14 M148 M
Vanguard Group IncCommon Shares13.8 M146.1 M
Baker Bros Advisors LpCommon Shares12.7 M134.5 M
State Street CorpCommon Shares11 M116.4 M
Avoro Capital Advisors LlcCommon Shares6.5 M68.8 M
Pictet Asset Management SaCommon SharesM64 M
Fisher Asset Management LlcCommon Shares5.2 M55.2 M
Note, although Biocryst Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Biocryst Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.22 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biocryst Pharma's market, we take the total number of its shares issued and multiply it by Biocryst Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Biocryst Profitablity

Biocryst Pharma's profitability indicators refer to fundamental financial ratios that showcase Biocryst Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Biocryst Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Biocryst Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Biocryst Pharma's profitability requires more research than a typical breakdown of Biocryst Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (103.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (93.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.94.

Management Efficiency

The entity has return on total asset (ROA) of (27.13) % which means that it has lost $27.13 on every $100 spent on asset. This is way below average. Biocryst Pharma management efficiency ratios could be used to measure how well biocryst pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 24th of September, Biocryst Pharma shows the Risk Adjusted Performance of 0.1411, mean deviation of 2.67, and Downside Deviation of 2.97. Biocryst Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Biocryst Pharma, which can be compared to its rivals. Please confirm Biocryst Pharma coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Biocryst Pharma is priced correctly, providing market reflects its regular price of 12.36 per share. Given that Biocryst Pharma has jensen alpha of 0.5294, we suggest you to validate Biocryst Pharma's prevailing market performance to make sure the company can sustain itself at a future point.

Biocryst Pharma Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Kaufman Adaptive Moving Average allows the user to define Biocryst Pharma range across which they want the smoothing.
.

Biocryst Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocryst Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocryst Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biocryst Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Theresa Heggie over a week ago via Macroaxis 
Acquisition by Theresa Heggie of 404 shares of Biocryst Pharma subject to Rule 16b-3
Theresa Heggie over two weeks ago via Macroaxis 
Acquisition by Theresa Heggie of 404 shares of Biocryst Pharma subject to Rule 16b-3
Mckee Amy E over three months ago via Macroaxis 
Acquisition by Mckee Amy E of 30022 shares of Biocryst Pharma subject to Rule 16b-3
Theresa Heggie over three months ago via Macroaxis 
Acquisition by Theresa Heggie of 1138 shares of Biocryst Pharma subject to Rule 16b-3
George Abercrombie over three months ago via Macroaxis 
Exercise or conversion by George Abercrombie of 5000 shares of Biocryst Pharma subject to Rule 16b-3
Thackray Helen M over three months ago via Macroaxis 
Sale by Thackray Helen M of 7600 shares of Biocryst Pharma
William Sheridan over six months ago via Macroaxis 
Exercise or conversion by William Sheridan of 148302 shares of Biocryst Pharma subject to Rule 16b-3
Yarlagadda Babu over six months ago via Macroaxis 
Sale by Yarlagadda Babu of 20000 shares of Biocryst Pharma
Jones Michael L over six months ago via Macroaxis 
Exercise or conversion by Jones Michael L of 2300 shares of Biocryst Pharma subject to Rule 16b-3
Theresa Heggie over six months ago via Macroaxis 
Acquisition by Theresa Heggie of 602 shares of Biocryst Pharma subject to Rule 16b-3
George Abercrombie over six months ago via Macroaxis 
Exercise or conversion by George Abercrombie of 5000 shares of Biocryst Pharma subject to Rule 16b-3
Sanders Machelle over six months ago via Macroaxis 
Acquisition by Sanders Machelle of 26667 shares of Biocryst Pharma subject to Rule 16b-3

Biocryst Pharma Predictive Daily Indicators

Biocryst Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Biocryst Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Biocryst Pharma Forecast Models

Biocryst Pharma time-series forecasting models is one of many Biocryst Pharma's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Biocryst Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Biocryst Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Biocryst Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Biocryst shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Biocryst Pharma. By using and applying Biocryst Stock analysis, traders can create a robust methodology for identifying Biocryst entry and exit points for their positions.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Biocryst Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 358 people.

Current Biocryst Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Biocryst analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Biocryst analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
19.82Buy11Odds
Biocryst Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Biocryst analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Biocryst stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Biocryst Pharma, talking to its executives and customers, or listening to Biocryst conference calls.
Biocryst Analyst Advice Details

Biocryst Stock Analysis Indicators

Biocryst Pharma stock analysis indicators help investors evaluate how Biocryst Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Biocryst Pharma shares will generate the highest return on investment. By understating and applying Biocryst Pharma stock analysis, traders can identify Biocryst Pharma position entry and exit signals to maximize returns.
Quick Ratio5.92
Fifty Two Week Low7.61
Revenue Growth161.90%
Shares Short Prior Month29.69M
Average Daily Volume Last 10 Day2.72M
Average Daily Volume In Three Month2.73M
Shares Percent Shares Out16.95%
Gross Margins-24.10%
Short Percent Of Float19.02%
Forward Price Earnings-16.05
Float Shares167.32M
Fifty Two Week High19.99
Enterprise Value To Ebitda-12.63
Fifty Day Average13.14
Two Hundred Day Average13.07
Enterprise Value To Revenue11.78
Continue to Trending Equities. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for analysis

When running Biocryst Pharma price analysis, check to measure Biocryst Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocryst Pharma is operating at the current time. Most of Biocryst Pharma's value examination focuses on studying past and present price action to predict the probability of Biocryst Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biocryst Pharma's price. Additionally, you may evaluate how the addition of Biocryst Pharma to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Is Biocryst Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocryst Pharma. If investors know Biocryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocryst Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biocryst Pharma is measured differently than its book value, which is the value of Biocryst that is recorded on the company's balance sheet. Investors also form their own opinion of Biocryst Pharma's value that differs from its market value or its book value, called intrinsic value, which is Biocryst Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocryst Pharma's market value can be influenced by many factors that don't directly affect Biocryst Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocryst Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Biocryst Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocryst Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.